SCHEMBL4616468

SCHEMBL4616468

CCCc1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)NCCc1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.60
LMNA P02545 6/20 0.60
ALDH1A1 P00352 5/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.55
TSHR P16473 1/20 0.55
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
SFRP1 Q8N474 2/20 0.49
TDP1 Q9NUW8 2/20 0.48
TAAR1 Q96RJ0 1/20 0.48
USP2 O75604 1/20 0.46
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618264 0.90 TDP1 (0.62) HTTLMNAALDH1A1MEN1KMT2A
SCHEMBL4617446 0.89 TAAR1 (0.63) ALDH1A1SFRP1TDP1TAAR1CYP1A2
SCHEMBL4638445 0.88 TBXAS1 (0.53) HTTLMNAALDH1A1MEN1KMT2A
SCHEMBL4617050 0.86 SFRP1 (0.67) HTTLMNAALDH1A1MEN1KMT2A
SCHEMBL4616751 0.83 ALDH1A1 (0.52) HTTLMNAALDH1A1MEN1KMT2A
SCHEMBL4617416 0.82 RAB9A (0.49) HTTSMN1; SMN2PKMSFRP1TAAR1
SCHEMBL4616698 0.82 SFRP1 (0.72) HTTALDH1A1SFRP1TAAR1POLB
SCHEMBL4639242 0.79 ALDH1A1 (0.56) LMNAALDH1A1KMT2ASFRP1POLB
SCHEMBL4616480 0.79 SFRP1 (0.58) HTTLMNAALDH1A1MEN1KMT2A
SCHEMBL4618887 0.77 SFRP1 (0.75) HTTALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 HTT 4703/4885LMNA 4608/4885ALDH1A1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.